Latest Regulation News

Australian Ethical Investment Limited (AEF) has responded to ASX inquiries about additional licence conditions imposed on its subsidiary, Australian Ethical Superannuation Pty Ltd (AES), asserting these do not materially affect its securities value despite a notable share price drop.

Critical Resources Limited’s maiden drilling at the Amoco Gold-Antimony Project confirms a substantial orogenic mineralised system, underpinning its exploration model and setting the stage for further work in NSW’s New England Fold Belt.

Emerald Resources has secured mining approval for its Dingo Range Gold Project in Western Australia and completed a major accommodation camp, marking significant progress toward its goal of becoming a multi-mine gold producer.

New Frontier Minerals has completed a $2.25 million placement to professional investors, issuing over 107 million shares and promising additional attaching options early next year. This capital injection aims to accelerate exploration at its key projects in the Northern Territory and Queensland.

Kjerulf David Hastings Ainsworth has initiated an unconditional all-cash proportional takeover offer for 2.9% of Ainsworth Game Technology Ltd shares at $1.30 each, representing a significant premium over recent trading prices and a competing bid by Novomatic.

Identitii Limited launches a $2.9 million rights issue, underwritten up to $2.3 million by its largest shareholder, to accelerate the commercial rollout of its BNDRY platform.

Pro Medicus has disclosed a contained data breach involving unauthorized access to a single employee email inbox, with limited exposure of personal information from around 100 current and former employees.

Chariot Resources has confirmed high-grade lithium mineralisation at its Fonlo and Iganna projects in Nigeria, with assays returning up to 5.96% lithium oxide. The results reinforce the potential for near-term production and resource expansion within its Nigerian lithium portfolio.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

Bendigo and Adelaide Bank reveals a strategic acquisition of RACQ Bank’s retail portfolio and outlines a comprehensive AML remediation plan, positioning itself for growth and enhanced operational resilience.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

6K Additive, Inc. launches a fully underwritten A$48 million IPO on the ASX, aiming to scale its innovative scrap-based metal powder production for additive manufacturing. The capital raise supports a major capacity expansion backed by a US Department of Defense grant.